Research
Hormonal
GLP-1 receptor agonists may increase the risk of adverse heart failure outcomes in patients with heart failure and reduced left ventricular ejection fraction (LVEF), despite showing cardiovascular benefits in other populations.
If you have heart failure with reduced ejection fraction, GLP-1RAs might increase your risk of heart failure complications. Always inform your doctor about your full heart history before starting these medications.
ModerateQualifiesMEDIUM confidence
There are two main trials (FIGHT and LIVE trials) demonstrating that treatment with liraglutide increased the risk of adverse heart failure-associated outcomes in patients with heart failure and reduced LVEF [43-45].
Why this rating
Based on specific trials (FIGHT, LIVE) which showed adverse outcomes, contrasting with broader CVOTs.
Source
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma et al. · International Journal of Biological Sciences · 2021
DOI 10.7150/ijbs.59965
narrative_reviewCited 267×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.Strong
- GLP-1 receptor agonists reduce blood pressure and improve lipid profiles (LDL-C, triglycerides), contributing to the stabilization of atherosclerotic plaques and reduced cardiovascular risk.Good
- GLP-1 receptor agonists exhibit protective effects on the kidneys by reducing the decline in estimated glomerular filtration rate (eGFR) and delaying the onset of proteinuria in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →